Association between Denosumab Therapy and Hypocalcemia: Influence of Concomitant Gastric Acid–Suppressive Agents and Other Clinical Parameters
Abstract
Denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor kappa B ligand, can cause hypocalcemia, necessitating calcium and vitamin D supplementation, and serum calcium monitoring. We examined the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on denosumab-induced hypocalcemia. Data were collected from Fukuoka University Hospital between January 1, 2018, and March 31, 2023. Data of patients who were prescribed denosumab were extracted and categorized into three groups: denosumab monotherapy, denosumab + PPI, and denosumab + H2RA. Each group was followed up for 30 d after initial administration. Data from 335 patients were analyzed, which revealed a higher incidence of hypocalcemia with PPIs (37/129 patients, 28.7%) and H2RAs (6/14 patients, 42.9%) than with denosumab monotherapy (34/192 patients, 17.7%). A Cox regression analysis indicated a significantly higher risk of hypocalcemia with PPIs (hazard ratio [HR] = 1.78, 95% confidence interval [CI]: 1.12-2.84) and H2RAs (HR = 2.94, 95% CI: 1.23-7.00) than with denosumab monotherapy. This study highlights the need for careful monitoring of serum calcium levels when denosumab is combined with gastric acid suppressants in patients treated with PPIs or H2RAs.
Related
- Genetic variants involved in sperm motility and their association with sperm motility parameters and risk of male infertility: a systematic review and meta-analysis protocol
- Association of Complete Blood Count Parameters and Systemic Inflammatory Indices with Early Surfactant Administration in Preterm Infants
- Association of Serum GDF-15 with Bone and Muscle Parameters in Community-Dwelling Individuals
- Changes in the CALLY Index After Sleeve Gastrectomy and Their Association with Weight Loss and Metabolic Parameters in Women
- Association of D-dimer, fibrin degradation products, and coagulation parameters with progressive hemorrhagic injury following traumatic brain injury : A retrospective cohort study
BibTeX
@article{morofuji2026association,
title = {{Association between Denosumab Therapy and Hypocalcemia: Influence of Concomitant Gastric Acid–Suppressive Agents and Other Clinical Parameters}},
author = {Riho Morofuji and Kohei Oyabu and Takuya Imatoh and Yuki Yasutaka and Tadahiro Ikeuchi and Susumu Kaneshige and Keisuke Migita and Kentaro Ogata and Hidetoshi Kamimura},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
month = jul,
doi = {10.1248/bpb.b25-00615},
url = {https://www.jstage.jst.go.jp/article/bpb/49/7/49_b25-00615/_article},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Association between Denosumab Therapy and Hypocalcemia: Influence of Concomitant Gastric Acid–Suppressive Agents and Other Clinical Parameters
AU - Riho Morofuji
AU - Kohei Oyabu
AU - Takuya Imatoh
AU - Yuki Yasutaka
AU - Tadahiro Ikeuchi
AU - Susumu Kaneshige
AU - Keisuke Migita
AU - Kentaro Ogata
AU - Hidetoshi Kamimura
PY - 2026
DA - 2026/07/09
JO - Biological and Pharmaceutical Bulletin
DO - 10.1248/bpb.b25-00615
UR - https://www.jstage.jst.go.jp/article/bpb/49/7/49_b25-00615/_article
AB - Denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor kappa B ligand, can cause hypocalcemia, necessitating calcium and vitamin D supplementation, and serum calcium monitoring. We examined the effects of proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) on denosumab-induced hypocalcemia. Data were collected from Fukuoka University Hospital between January 1, 2018, and March 31, 2023. Data of patients who were prescribed denosumab were extracted and categorized into three groups: denosumab monotherapy, denosumab + PPI, and denosumab + H2RA. Each group was followed up for 30 d after initial administration. Data from 335 patients were analyzed, which revealed a higher incidence of hypocalcemia with PPIs (37/129 patients, 28.7%) and H2RAs (6/14 patients, 42.9%) than with denosumab monotherapy (34/192 patients, 17.7%). A Cox regression analysis indicated a significantly higher risk of hypocalcemia with PPIs (hazard ratio [HR] = 1.78, 95% confidence interval [CI]: 1.12-2.84) and H2RAs (HR = 2.94, 95% CI: 1.23-7.00) than with denosumab monotherapy. This study highlights the need for careful monitoring of serum calcium levels when denosumab is combined with gastric acid suppressants in patients treated with PPIs or H2RAs.
SN - 1347-5215
SN - 0918-6158
ER -